Search Results
Onco
Daily
Facebook
RSS
X
Youtube
Linkedin
September, 2024
September 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
« Aug
Dana-Farber Cancer Institute
Apr 14, 2024, 13:47 |
Insight
Paolo Tarantino: Do patients with these small triple-negative tumors benefit from chemotherapy?
Paolo Tarantino, Research Fellow presso Dana-Farber Cancer Institute, shared a post on LinkedIn: "One third of…
Apr 14, 2024, 12:05
OncoDaily Party 2024
OncoDaily Party 2024: Summer is Coming May 31, 2024: Registration from 7:30 PM to 8:30…
Apr 14, 2024, 10:33 |
Opinion
Elad Sharon: Designing clinical trials is all about tradeoffs
Elad Sharon, Clinical and Translational Director of Immunotherapy Toxicity Service at Dana-Farber Cancer Institute, shared…
Apr 12, 2024, 03:19 |
Dialogues
OncoInfluencers: Dialogue with Pasi Jänne, hosted by Gevorg Tamamyan
Join us for an exciting new episode of “OncoInfluencers,” hosted by Dr. Gevorg Tamamyan. In…
Apr 11, 2024, 17:15 |
Blog
Oyepeju Abioye: 'Precision Immuno-Oncology in NSCLC through Gender Equity Lenses', published in MDPI
Oyepeju Abioye, Oncology Clinical Research Assistant at Florez Laboratory of Dana-Farber Cancer Institute, shared on X:…
Apr 11, 2024, 13:38 |
Blog
Paolo Tarantino: Wonderful and fun discussions on ADCs at AACR24 with Helena Yu and Petros Grivas
Paolo Tarantino, Advanced Research Fellow in the Breast Oncology Program at Dana-Farber Cancer Institute, shared a…
Apr 11, 2024, 12:21 |
Blog
Paolo Tarantino: Easier to get a ticket for a Taylor Swift concert than to find a seat at the AACR24 Next Generation ADC session!
Paolo Tarantino, Advanced Research Fellow in the Breast Oncology Program at Dana-Farber Cancer Institute, shared…
Apr 10, 2024, 05:00 |
Blog
Paolo Tarantino: Our study on the prognosis of small TNBCs is out in NPJ Journals
Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, shared a post on X: "Our study…
Apr 9, 2024, 13:33 |
Blog
Biagio Ricciuti: If you are at AACR24, stop by poster 21 (section 1) to learn more about the discovery of ALK-specific TCR clonotypes
Biagio Ricciuti, Medical Oncologist at Dana-Farber Cancer Institute, shared on X/Twitter: ''If you are at…
Apr 8, 2024, 23:10 |
Blog
Biagio Ricciuti: MET kinase domain mutations as novel and targetable alterations in NSCLC
Biagio Ricciuti, Medical oncologist at Dana-Farber Cancer Institute, shared a post on LinkedIn: "Our collaborative effort…
61
62
63
64
65
All:
748
Posts:
621 - 630
Top 100 Xfluencers in Pediatric Hematology/Oncology: Key Opinion Leaders to follow on X (Twitter) in 2024
Jeff Bridges and Lymphoma: How He Went Against, How He Survived, and More
100 Influential Women in Oncology: Key Opinion Leaders to Follow on Social Media in 2024: Part 5
Familial Adenomatous Polyposis: Alarming Symptoms, Causes, Types, Diagnosis and Treatment
OncoDaily Party Barcelona
Special Coverage
ASCO Annual Meeting
May 30 - June 4, 2024
Yvonne Award 2024
May 31, 2024
OncoThon 2024, Online
Feb. 15, 2024
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Facebook
RSS Feed
X
Linkedin
Youtube